The article may have been published today but, it seems the author hadn't checked the pps recently:
The company currently trades at $0.50 per share, and we expect it to increase in share price in 2014.
I'm not sure the author presented anything "new." It seems that a number of known points were simply "recycled" from various other sources.
This is true:
If the platform proves to be successful in a final clinical outcome in phase 3 then this small cap biotechnology company will for sure be a game changer in the biotech industry.
$ONCS
All IMO.
Saving up your money for a rainy day, Giving all your clothes to charity. Last night the wife said, "Oh boy, when you're dead You don't take nothing with you But your soul - think!" (Lennon/McCartney, "The Ballad of John and Yoko")